PPLPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.3
| Stock Code | PPLPHARMA | Market Cap | 21,401 Cr. | Current Price | 161 ₹ | High / Low | 241 ₹ |
| Stock P/E | 29.0 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 170 ₹ | DMA 200 | 189 ₹ |
| Chg in FII Hold | -0.61 % | Chg in DII Hold | 0.79 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 47.0 | MACD | -5.26 | Volume | 40,94,856 | Avg Vol 1Wk | 57,50,649 |
| Low price | 148 ₹ | High price | 241 ₹ | PEG Ratio | 1.31 | Debt to equity | 0.12 |
| 52w Index | 13.9 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 29.2 |
📊 PPLPHARMA shows moderate fundamentals with weak technicals, making it a cautious candidate for swing trading. The stock is currently at ₹161, trading below both its 50 DMA (₹170) and 200 DMA (₹189), reflecting bearish sentiment. RSI at 47.0 is neutral, while MACD at -5.26 indicates mild downward momentum. With fair valuation (P/E 29.0 vs industry 29.2) and modest ROCE/ROE, fundamentals provide some support. Optimal entry would be in the ₹155–₹160 range. If already holding, exit near ₹175–₹185, where resistance from the 50 DMA is expected.
✅ Positive
- P/E of 29.0 is aligned with industry PE (29.2), suggesting fair valuation.
- ROCE (12.4%) and ROE (9.74%) show moderate efficiency.
- DII holdings increased (+0.79%), showing domestic institutional support.
- Debt-to-equity ratio at 0.12 indicates low leverage risk.
- PEG ratio of 1.31 suggests reasonable valuation relative to growth.
⚠️ Limitation
- Stock trading below both 50 DMA and 200 DMA shows technical weakness.
- Dividend yield of 0.09% offers negligible income return.
- EPS of ₹5.39 is modest compared to peers.
- Volume below weekly average indicates reduced participation.
📉 Company Negative News
- Quarterly PAT declined from ₹196 Cr. to ₹151 Cr.
- FII holdings decreased (-0.61%), showing reduced foreign investor confidence.
- 52-week index at 13.9% highlights underperformance relative to peers.
📈 Company Positive News
- Quarterly profit variance (+27.4% YoY) shows improvement despite sequential decline.
- DII inflows (+0.79%) reflect confidence from domestic institutions.
- Debt-to-equity ratio remains low, ensuring financial stability.
🏭 Industry
- Industry PE at 29.2 is in line with PPLPHARMA’s 29.0, suggesting fair valuation.
- Pharmaceutical sector remains resilient, supported by healthcare demand and exports.
🔎 Conclusion
PPLPHARMA is a moderate swing candidate with fair valuation but weak technicals. Entry near ₹155–₹160 offers margin of safety. Exit around ₹175–₹185 is advisable if already holding, as resistance is expected near the 50 DMA. Risk management is essential due to declining quarterly profits and bearish momentum indicators.